~~<i id='26FA52E02A'><strike id='26FA52E02A'><tt id='26FA52E02A'><pre id='26FA52E02A'></pre></tt></strike></i>~~

Home» comprehensive» entertainment

entertainment

author：comprehensive 2025-09-30 14:55:26 Page View：9

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Mifepristone protocols being wielded by pill's opponents in Supreme Court case
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

knowledge

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

NEJM study measures Covid brain fog, impact on IQ

AdobeOfallthelingeringsymptomsoflongCovid,difficultyfocusingandthinking,knownasbrainfog,maybethemost

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

FILE-Myanmar'sleaderAungSanSuuKyi,left,attendsthebilateralmeetingwithChinesePresidentXiJinpingatthep

WSS

entertainment

entertainment

explore

knowledge

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi